LDL apheresis for familial hypercholesterolemia: Value, indications and demand

Future Lipidology

Volumn 4, Issue 2, 2009, Pages 129-131

  Watts, Gerald F ^a   Hamilton, Sandra J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANEMIA; APHERESIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DISEASE CONTROL; DISEASE SEVERITY; DRUG MECHANISM; EARLY DIAGNOSIS; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH CARE COST; HUMAN; LOW DENSITY LIPOPROTEIN APHERESIS; PATIENT SAFETY; PREGNANT WOMAN; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 67249093670     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.7     Document Type: Editorial

References (15)

1. Rader DJ, Cohen J, Hobbs HH: Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111, 1795 (2003).
2. Marks D, Thorogood M, Neil HA, Humphries SE: A review on the diagnosis, natural history, and treatment of familial hypercholesterolemia. Atherosclerosis 168, 1-14 (2003).
3. Civeira F: Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173, 55-68 (2004)
4. Wierzbicki AS, Humphries SE, Minhas R: Familial hypercholesterolemia: summary of NICE guidance. Br. Med. J. 337,509-510 (2008).
5. Watts GF, Lewis B, Sullivan DR: Familial hypercholesterolemia: a missed opportunity in preventive medicine. Nat. Clin. Pract. Cardiovasc. Med. 4(4),404-405 (2007).
6. Thompson GR, Heart UK LDL Apheresis Working Group: Recommendations for the use of LDL apheresis. Atherosclerosis 198, 247-255 (2008).
7. Szczepiorkowski ZM, Bandarenko N, Kim HC et al.: Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J. Clin. Apheresis 22, 106-175 (2007).
8. Gordon BR, Saal SD: Advances in LDL-apheresis for the treatment of severe. hypercholesterolemia. Curr. Opin. Lipidology 5, 69-73 (1994).
9. Thompson GR, Lowenthal R, Myant NB: Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet1(7918),1208-1211 (1975).
10. Thompsen J, Thompson PD: A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 189, 31-38 (2006).
11. Mabuchi H, Higashikata T, Kawashiri MA: Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia. Transfus. Apher. Sci. 30, 233-243 (2004).
12. Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR: Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am. J. Cardiol. 102, 1199-1204 (2008).
13. Stefanutti C, Lanti A, Di Giacomo S et al.: Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks. Transfus. Apher. Sci. 31,3-10 (2004).
14. Sinzingera H, Bednar J, Granegger S, Blazek I, Peskar BA: LDL-apheresis and concomitant ACE-inhibitor therapy. Atherosclerosis 105, 115-116 (1994).
15. Cashin-Hemphill L, Noone M, Abbott JF, Waksmonski CA, Lees RS: Low-density lipoprotein apheresis therapy during pregnancy. Am. J. Cardiol. 86, 1160 (2000).